1. Home
  2. MYND vs ALLR Comparison

MYND vs ALLR Comparison

Compare MYND & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mynd.ai Inc.

MYND

Mynd.ai Inc.

BUY

Current Price

$0.24

Market Cap

17.9M

Sector

Real Estate

ML Signal

BUY

Logo Allarity Therapeutics Inc.

ALLR

Allarity Therapeutics Inc.

HOLD

Current Price

$0.85

Market Cap

19.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MYND
ALLR
Founded
1998
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.9M
19.3M
IPO Year
2017
2021

Fundamental Metrics

Financial Performance
Metric
MYND
ALLR
Price
$0.24
$0.85
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 204.0K
117.9K
Earning Date
08-27-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $320,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.00
$0.77
52 Week High
$0.72
$1.84

Technical Indicators

Market Signals
Indicator
MYND
ALLR
Relative Strength Index (RSI) 40.55 34.12
Support Level N/A $0.79
Resistance Level $0.35 $1.28
Average True Range (ATR) 0.06 0.07
MACD -0.01 0.00
Stochastic Oscillator 65.43 24.04

Price Performance

Historical Comparison
MYND
ALLR

About MYND Mynd.ai Inc.

Mynd.ai Inc provides world'wide, end-to-end, learning solutions and collaboration tools to help teachers, schools, students, and professionals realize their greatest potential. The company has single reporting segment. The company has presence in United States and Rest of world. The company generates majority of revenue from United States.

About ALLR Allarity Therapeutics Inc.

Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.

Share on Social Networks: